Recent Updates
Recently added Catalysts

Loxoprofen

Phase 3

Low Back Pain | Small molecule | Pain |Pfizer, Inc.|Last Updated: Mar 3, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment1,234

FDA Designations

No designations recorded

Clinical trial landscape

Loxoprofen · 1 trial · 1 indication

Phase 3 1
NCT00141154Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In JapanLow Back Pain
COMPLETED1,234 Analytics
PHASE3COMPLETED
Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
Low Back Pain
NCT001411541,234
Unlock trial analytics

Study Endpoints

Primary Endpoints

Patient's pain assessment (VAS: Visual Analogue Scale)

Secondary Endpoints

Patient's global assessment (VAS), Physician's global assessment (VAS), Roland Morris Disability Questionnaire (RDQ)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
CelecoxibDRUG -
PlaceboDRUG -
LoxoprofenDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites38

Inclusion Criteria: * Patients who have the major site of the low back pain at the 12th thoracic vertebra or lower * Patients who have had low back pain for at least two weeks Exclusion Criteria: * Patients who have a previous history or complication of rheumatoid arthritis, spondylarthrosis with...

Countries:Japan
Unlock Eligibility Criteria

Competitive Landscape -Low Back Pain 8 trials

CompanyTickerTrialsLead PhaseDrugs
Hinge Health, Inc. Class AHNGE1N/AUndisclosed
Stryker CorporationSYK1 - Undisclosed
Boston Scientific CorporationBSX1N/AUndisclosed
Aclarion, Inc.ACON1 - Undisclosed
United Therapeutics CorporationUTHR1N/AUndisclosed
eHealth, Inc.EHTH1N/AUndisclosed
Unlock Competitive Intelligence

Frequently asked questions about Loxoprofen

What is Loxoprofen used for?

Loxoprofen is a small molecule drug being developed for the treatment of low back pain. It is currently in Phase 3 clinical development and is being studied in Japan. The drug is being evaluated in a clinical trial that compares it to celecoxib and placebo in patients with low back pain.

What does Loxoprofen target?

Loxoprofen is a small molecule drug being studied for low back pain. The specific molecular target of Loxoprofen has not been disclosed in the available information. The drug is being evaluated in a Phase 3 clinical trial in Japan.

Who makes Loxoprofen?

Loxoprofen is being developed by Pfizer, Inc., a company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the treatment of low back pain.

What phase is Loxoprofen in?

Loxoprofen is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of low back pain. The drug has completed one Phase 3 clinical trial, and it is not yet approved by regulatory authorities.

What clinical trials is Loxoprofen in?

Loxoprofen has been studied in one completed Phase 3 clinical trial with the identifier NCT00141154. This trial, titled 'Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan,' enrolled 1234 participants and was conducted in Japan.

Is Loxoprofen the same as Loxoprofen Sodium?

Loxoprofen is the drug name, and the clinical trial for low back pain specifically studied Loxoprofen Sodium at a dose of 60 mg three times daily. The trial compared Loxoprofen Sodium to celecoxib and placebo in patients with low back pain.